The conflict over conflicts
By Tali Woodward,
San Francisco Bay Guardian
| 04. 14. 2005
The stem cell institute moves to rein in conflicts of interest, but some concerns remain The state committee that will hand out $3 billion in grants for stem cell research adopted policies April 7 that are meant to prevent conflicts of interest. But critics still worry that the California Institute for Regenerative Medicine (CIRM) will be compromised by the committee's abundant connections to biotech, which its members will largely be allowed to maintain.
More than 10 of the 29 committee members work for or are heavily invested in biomedical companies with some interest in stem cell work. Several others are affiliated with nonprofit institutions doing research on stem cells (see "Celling Out," 4/6/05).
Under the new rules, committee members must disclose all financial interests and then recuse themselves from voting on any decision that involves their employer or "financially benefits the member or the entity he or she represents." They're also forbidden to approve grants that could have a "material financial effect" on their family.
see moreCIRM watchdogs like the Center for Genetics and Society say that while the new policies...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...